Key statistics dashboard for Dyadic International, Inc. (DYAI). Valuation multiples (P/E, P/B, EV/EBITDA), profitability margins, financial-health ratios, per-share metrics and stock-level data in one consolidated view — the snapshot quantitative analysts and value investors check first.
Dyadic International, Inc. operates as a U.S.-based biotechnology platform company, specializing in the development, production, and commercialization of enzymes and other proteins. Its core activities are underpinned by a patented and proprietary C1 platform, alongside other advanced technologies.
Stock Data
| Price | $0.40 |
| Market Cap | $15M |
| Enterprise Value | $18.3M |
| Beta | 1.21 |
| Exchange | NASDAQ |
| Country | US |
Valuation Multiples
| P/E Ratio | -1.89 |
| Price / Book | -6.15 |
| P/S | 4.22 |
| EV/EBITDA | -2.55 |
| EV/Sales | 5.27 |
| EV/FCF | -2.47 |
| P/FCF | -1.98 |
| Earnings Yield | -51.95% |
| FCF Yield | -50.47% |
| Dividend Yield | 0.00% |
Profitability
| Gross Margin | 30.44% |
| EBIT Margin | -207.43% |
| EBITDA Margin | -206.90% |
| Operating Margin | -213.59% |
| Net Margin | -219.50% |
| Return on Equity | -2918.10% |
| Return on Assets | -116.60% |
| Return on Invested Capital | -278.95% |
| Return on Capital Employed | -279.48% |
Financial Health
| Current Ratio | 1.65 |
| Quick Ratio | 1.65 |
| Cash Ratio | 0.37 |
| Debt / Equity | -2.11 |
| Debt / Assets | 77.20% |
| Net Debt / EBITDA | -0.50 |
| Interest Coverage | -17.71 |
Per-Share Data
| Revenue per share | 0.10 |
| Book Value per share | -0.07 |
| Cash per share | 0.09 |
| FCF per share | -0.20 |
| Tangible Book Value per share | -0.07 |
| Dividend per share | 0.00 |
Related companies: ANVS · ATHE · BCAB · CELU · ELUT · MAIA · PYPD
Explore sector: Healthcare · Biotechnology
More sections of DYAI: Overview · Financials · Valuation · Estimates · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks